|
1
|
Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF
and Gu KS: Multidrug resistance in leukemic cell line K562/A02
induced by doxorubicin. Zhongguo Yao Li Xue Bao. 16:333–337.
1995.PubMed/NCBI
|
|
2
|
Hackl H, Astanina K and Wieser R:
Molecular and genetic alterations associated with therapy
resistance and relapse of acute myeloid leukemia. J Hematol Oncol.
10:512017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalton WS: Mechanisms of drug resistance
in hematologic malignancies. Semin Hematol. 34 4 Suppl 5:S3–S8.
1997.
|
|
4
|
Young AM, Allen CE and Audus KL: Efflux
transporters of the human placenta. Adv Drug Deliv Rev. 55:125–132.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SY, Rhee YH, Jeong SJ, Lee HJ, Lee HJ,
Jung MH and Kim SH, Lee EO, Ahn KS, Ahn KS and Kim SH:
Hydrocinchonine, cinchonine, and quinidine potentiate
paclitaxel-induced cytotoxicity and apoptosis via multidrug
resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ
Toxicol. 26:424–431. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dönmez Y, Akhmetova L, Iseri ÖD, Kars MD
and Gündüz U: Effect of MDR modulators verapamil and promethazine
on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant
MCF-7 cells. Cancer Chemother Pharmacol. 67:823–828. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wibowo M, Levrier C, Sadowski MC, Nelson
CC, Wang Q, Holst J, Healy PC, Hofmann A and Davis RA: Bioactive
dihydro-β-agarofuran sesquiterpenoids from the Australian
rainforest plant Maytenus bilocularis. J Nat Prod.
79:1445–1453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pajeva I and Wiese M: Molecular modeling
of phenothiazines and related drugs as multidrug resistance
modifiers: A comparative molecular field analysis study. J Med
Chem. 41:1815–1826. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schondörf T, Kurbacher CM, Göhring UJ,
Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P and Neumann R:
Induction of MDR1-gene expression by antineoplastic agents in
ovarian cancer cell lines. Anticancer Res. 22:2199–2203.
2002.PubMed/NCBI
|
|
10
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anuchapreeda S, Leechanachai P, Smith MM,
Ambudkar SV and Limtrakul PN: Modulation of P-glycoprotein
expression and function by curcumin in multidrug-resistant human KB
cells. Biochem Pharmacol. 64:573–582. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu ST, Chen TM, Tseng SY and Chen YH:
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in
breast cancer cells. Biochem Biophys Res Commun. 358:79–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mutoh K, Tsukahara S, Mitsuhashi J,
Katayama K and Sugimoto Y: Estrogen-mediated post transcriptional
down-regulation of P-glycoprotein in MDR1-transduced human breast
cancer cells. Cancer Sci. 97:1198–1204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou YG, Li KY and Li HD: Effect of the
novel antipsychotic drug perospirone on P-glycoprotein function and
expression in Caco-2 cells. Eur J Clin Pharmacol. 64:697–703. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baldwin EL and Osheroff N: Etoposide,
topoisomerase II and cancer. Curr Med Chem Anticancer Agents.
5:363–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hande KR: Etoposide: Four decades of
development of a topoisomerase II inhibitor. Eur J Cancer.
34:1514–1521. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi K and Ratain MJ:
Pharmacodynamics and long-term toxicity of etoposide. Cancer
Chemother Pharmacol. 34 Suppl:S64–S68. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith MA, Rubinstein L, Anderson JR,
Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land
VJ, et al: Secondary leukemia or myelodysplastic syndrome after
treatment with epipodophyllotoxins. J Clin Oncol. 17:569–577. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choudhury RC, Palo AK and Sahu P:
Cytogenetic risk assessment of etoposide from mouse bone marrow. J
Appl Toxicol. 24:115–122. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Attia SM, Al-Anteet AA, Al-Rasheed NM,
Alhaider AA and Al-Harbi MM: Protection of mouse bone marrow from
etoposide-induced genomic damage by dexrazoxane. Cancer Chemother
Pharmacol. 64:837–845. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kapiszewska M, Cierniak A, Papiez MA,
Pietrzycka A, Stepniewski M and Lomnicki A: Prolonged quercetin
administration diminishes the etoposide-induced DNA damage in bone
marrow cells of rats. Drug Chem Toxicol. 30:67–81. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enomoto R, Koshiba C, Suzuki C and Lee E:
Wogonin potentiates the antitumor action of etoposide and
ameliorates its adverse effects. Cancer Chemother Pharmacol.
67:1063–1072. 2011. View Article : Google Scholar : PubMed/NCBI
|
